Celaid raises $2.54M to advance pediatric HSC therapy
What's the deal? Tokyo-based Celaid Therapeutics has completed the second close of its Series B round, raising US$3.08M. New investors ShionogiDealroom has a profile for this one. Try Dealroom → and Teikoku Ventures backed the biotech, which develops treatments for severe pediatric non-malignant diseases.
What's the endgame? Celaid is building hematopoietic stem cell (HSC) therapies, with lead candidate CLD-001. The latest funds advance that work toward treating children with serious non-cancer conditions.
By the numbers: Celaid's cumulative capital now stands at roughly US$26.3M (around $22.1 million), including grants. It has also secured Stage 3 funding from the Japan Agency for Medical Research and DevelopmentDealroom has a profile for this one. Try Dealroom →.
The signal: At about $2.54 million, this close sits in the lower tier of biotech rounds — a reminder that early-stage therapeutics in Japan often lean on a mix of strategic pharma backing and government grants to progress. Shionogi's participation signals pharma interest in the cell therapy niche.
Read more: third-news.com
Image credit: Tareq Salahuddin
